LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 213

Search options

  1. Article ; Online: Immunologic prediction of long COVID.

    Cron, Randy Q

    Nature immunology

    2023  Volume 24, Issue 2, Page(s) 207–208

    MeSH term(s) Humans ; COVID-19 ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; Hospitalization
    Language English
    Publishing date 2023-01-30
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2016987-5
    ISSN 1529-2916 ; 1529-2908
    ISSN (online) 1529-2916
    ISSN 1529-2908
    DOI 10.1038/s41590-022-01396-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: No perfect therapy for the imperfect COVID-19 cytokine storm.

    Cron, Randy Q

    The Lancet. Rheumatology

    2022  Volume 4, Issue 5, Page(s) e308–e310

    Language English
    Publishing date 2022-03-29
    Publishing country England
    Document type Journal Article
    ISSN 2665-9913
    ISSN (online) 2665-9913
    DOI 10.1016/S2665-9913(22)00068-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Double-barrel targeting of IFN-γ to treat hemophagocytic lymphohistiocytosis.

    Cron, Randy Q

    The Journal of allergy and clinical immunology

    2022  Volume 151, Issue 1, Page(s) 106–107

    MeSH term(s) Humans ; Lymphohistiocytosis, Hemophagocytic/drug therapy ; Cytokines ; Interferon-gamma
    Chemical Substances Cytokines ; Interferon-gamma (82115-62-6)
    Language English
    Publishing date 2022-11-05
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 121011-7
    ISSN 1097-6825 ; 1085-8725 ; 0091-6749
    ISSN (online) 1097-6825 ; 1085-8725
    ISSN 0091-6749
    DOI 10.1016/j.jaci.2022.10.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The Multifaceted Immunology of Cytokine Storm Syndrome.

    Lee, Pui Y / Cron, Randy Q

    Journal of immunology (Baltimore, Md. : 1950)

    2024  Volume 210, Issue 8, Page(s) 1015–1024

    Abstract: Cytokine storm syndromes (CSSs) are potentially fatal hyperinflammatory states that share the underpinnings of persistent immune cell activation and uninhibited cytokine production. CSSs can be genetically determined by inborn errors of immunity (i.e., ... ...

    Abstract Cytokine storm syndromes (CSSs) are potentially fatal hyperinflammatory states that share the underpinnings of persistent immune cell activation and uninhibited cytokine production. CSSs can be genetically determined by inborn errors of immunity (i.e., familial hemophagocytic lymphohistiocytosis) or develop as a complication of infections, chronic inflammatory diseases (e.g., Still disease), or malignancies (e.g., T cell lymphoma). Therapeutic interventions that activate the immune system such as chimeric Ag receptor T cell therapy and immune checkpoint inhibition can also trigger CSSs in the setting of cancer treatment. In this review, the biology of different types of CSSs is explored, and the current knowledge on the involvement of immune pathways and the contribution of host genetics is discussed. The use of animal models to study CSSs is reviewed, and their relevance for human diseases is discussed. Lastly, treatment approaches for CSSs are discussed with a focus on interventions that target immune cells and cytokines.
    MeSH term(s) Animals ; Humans ; Cytokine Release Syndrome/complications ; Lymphohistiocytosis, Hemophagocytic ; Cytokines ; Neoplasms ; Arthritis, Juvenile
    Chemical Substances Cytokines
    Language English
    Publishing date 2024-04-16
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 3056-9
    ISSN 1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381
    ISSN (online) 1550-6606
    ISSN 0022-1767 ; 1048-3233 ; 1047-7381
    DOI 10.4049/jimmunol.2200808
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children.

    Cron, Randy Q

    Current opinion in rheumatology

    2022  Volume 34, Issue 5, Page(s) 274–279

    Abstract: Purpose of review: Multisystem inflammatory syndrome in children (MIS-C) is a postinfectious complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primarily affecting children. MIS-C shares features with Kawasaki disease ...

    Abstract Purpose of review: Multisystem inflammatory syndrome in children (MIS-C) is a postinfectious complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primarily affecting children. MIS-C shares features with Kawasaki disease (KD) and cytokine storm syndrome (CSS) frequently requiring intensive care support. Although intravenous immunoglobulin (IVIg) and glucocorticoids (GCs) are effective therapeutics for most, refractory MIS-C is treated with various biologic disease-modifying antirheumatic drugs (bDMARDs). Understanding the clinical features, inflammatory cytokines, and genetic associations provides rationale for bDMARD in treating severe MIS-C.
    Recent findings: Children with MIS-C have clinical KD features and often present in hypovolemic and cardiogenic shock requiring volume repletion (gastrointestinaI losses) and cardiac pressor support (epinephrine). Investigation of MIS-C serum reveals elevated pro-inflammatory cytokines [interleukin (IL)-1, IL-6, IL-18, interferon gamma (IFNγ), tumor necrosis factor (TNF)], but to a lesser extent than other established CSS. Gene sequencing of MIS-C children identifies heterozygous mutations in CSS associated genes. Treatment of refractory (IVIg and GC) MIS-C with bDMARDs to IL-1, IL-6, and TNF is efficacious for survival as well as resolving cardiac and coronary artery inflammation.
    Summary: MIS-C is a postinfectious complication of SARS-CoV-2 resembling KD and CSS, both genetically and by pro-inflammatory cytokines. MIS-C that is refractory to IVIg and GC is routinely responsive to bDMARDs targeting IL-1, IL-6, and TNF.
    MeSH term(s) Antirheumatic Agents ; Biological Products/therapeutic use ; COVID-19/complications ; Child ; Cytokine Release Syndrome ; Cytokines ; Humans ; Immunoglobulins, Intravenous/therapeutic use ; Interleukin-1 ; Interleukin-6 ; Mucocutaneous Lymph Node Syndrome/complications ; SARS-CoV-2 ; Systemic Inflammatory Response Syndrome ; Tumor Necrosis Factor-alpha ; COVID-19 Drug Treatment
    Chemical Substances Antirheumatic Agents ; Biological Products ; Cytokines ; Immunoglobulins, Intravenous ; Interleukin-1 ; Interleukin-6 ; Tumor Necrosis Factor-alpha
    Language English
    Publishing date 2022-07-05
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 1045317-9
    ISSN 1531-6963 ; 1040-8711
    ISSN (online) 1531-6963
    ISSN 1040-8711
    DOI 10.1097/BOR.0000000000000889
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: COVID-19 cytokine storm: targeting the appropriate cytokine.

    Cron, Randy Q

    The Lancet. Rheumatology

    2021  Volume 3, Issue 4, Page(s) e236–e237

    Language English
    Publishing date 2021-02-03
    Publishing country England
    Document type Journal Article
    ISSN 2665-9913
    ISSN (online) 2665-9913
    DOI 10.1016/S2665-9913(21)00011-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Anakinra at the heart of the matter in MIS-C.

    Reiff, Daniel D / Cron, Randy Q

    Rheumatology (Oxford, England)

    2023  Volume 63, Issue 2, Page(s) 275–276

    MeSH term(s) Humans ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; Heart ; Treatment Outcome ; COVID-19 ; Systemic Inflammatory Response Syndrome
    Chemical Substances Interleukin 1 Receptor Antagonist Protein
    Language English
    Publishing date 2023-09-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/kead475
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Janus kinase inhibition in juvenile idiopathic arthritis.

    Rife, Eileen C / Cron, Randy Q

    Lancet (London, England)

    2023  Volume 402, Issue 10401, Page(s) 508–509

    MeSH term(s) Humans ; Arthritis, Juvenile/drug therapy ; Janus Kinase Inhibitors/therapeutic use
    Chemical Substances Janus Kinase Inhibitors
    Language English
    Publishing date 2023-07-06
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(23)01134-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Coronavirus is the trigger, but the immune response is deadly.

    Cron, Randy Q

    The Lancet. Rheumatology

    2020  Volume 2, Issue 7, Page(s) e370–e371

    Keywords covid19
    Language English
    Publishing date 2020-05-29
    Publishing country England
    Document type Journal Article
    ISSN 2665-9913
    ISSN (online) 2665-9913
    DOI 10.1016/S2665-9913(20)30165-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Cytokine Storm Syndrome Triggered by Extracorporeal Membrane Oxygenation in Pediatric Patients.

    Reiff, Daniel D / Cron, Randy Q

    Children (Basel, Switzerland)

    2023  Volume 10, Issue 6

    Abstract: Cytokine storm syndrome (CSS) is a serious and potentially life-threatening condition caused by severe systemic inflammation, immune activation, and a positive feedback loop of cytokine release. Typically triggered by systemic infection, malignancy, ... ...

    Abstract Cytokine storm syndrome (CSS) is a serious and potentially life-threatening condition caused by severe systemic inflammation, immune activation, and a positive feedback loop of cytokine release. Typically triggered by systemic infection, malignancy, monogenic or rheumatic disease, similar patterns of hyper-inflammation have been seen in patients undergoing cardiopulmonary bypass (CPB) and in patients treated with extracorporeal membrane oxygenation (ECMO). Typical treatments used for the prevention and treatment of CPB/ECMO-induced hyper-inflammation have not been shown to be substantially effective. Two patients suffering from ECMO-related CSS were identified by their severe hyper-inflammatory profile and life-threatening sequelae of vasodilatory shock and respiratory failure. Anakinra, an interleukin-1 receptor antagonist, was employed as specific cytokine-directed therapy for the treatment of CSS in these two patients to good effect, with significant improvement in hyper-inflammation and cardiorespiratory status. The use of cytokine-directed therapies in CPB/ECMO-related CSS has great potential to improve the treatment and outcomes of this serious condition.
    Language English
    Publishing date 2023-06-13
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2732685-8
    ISSN 2227-9067
    ISSN 2227-9067
    DOI 10.3390/children10061052
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top